We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BCGite, uma complicação rara do tratamento intravesical com bacilo de Calmette-Guérin.
- Authors
Ana Canelas, Maria; Salvador, Pedro; Rita Amorim, Ana; Rita Barbosa, Ana; Reis, Marina; Borges, Filipa; Beça, Sara; Furtado, Antónia; Gonçalves, Olga; Mota, Margarida
- Abstract
Introduction: Bladder carcinoma it is the seventh most frequent cancer in Portugal. Initially produced as a vaccine for tuberculosis, the Calmette-Guérin bacillus (CGB), a live attenuated strain of Mycobacterium bovis, has been widely used as immunotherapy in the last decades. It constitutes the core treatment in bladder cancer. Secondary effects are present in 5% of cases. Case report: 73-year-old Caucasian male, undergoing treatment with intravesical CGB for a year, due to a high-grade transition cell carcinoma. He went to the Emergency Department presenting with fever and shivering for two weeks. The investigation supported the diagnosis of BCGitis with systemic dissemination. He was then started on anti-tuberculous drugs, with clinical and analytical improvement. Conclusion: Treatment using CGB is safe; however, despite rare, BCGitis must be part of the differential diagnosis in these patients. Systemic dissemination is rare, and results from the combination of the infection itself, with a hypersensitivity reaction, that explains the low performance of microbiological study. Its therapeutic approach is not consensual, but in severe cases it has been recommended the immediate initiation of anti-tuberculous drugs and intravenous steroids.
- Publication
RPDI - Revista Portuguesa de Doenças Infecciosas, 2018, Vol 14, Issue 3, p111
- ISSN
0870-1571
- Publication type
Academic Journal